I was only joking. I like ENTA's chances in NASH because the company's drug-designers have proven expertise in liver diseases, but the NASH program is not the reason I'm long.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.